Corcept Reports Favorable Survival and Response Data in Ovarian Cancer Study
Corcept Therapeutics reported positive Phase 2 BELLA trial data for Lifyorli and chemotherapy in platinum-resistant ovarian cancer patients.
Share
Why It Matters
Corcept's cancer medicine showed good results in a patient study. This suggests the treatment might help sick people, which is encouraging news for the company.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.